Literature DB >> 533577

Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.

D H Wiles, M G Gelder.   

Abstract

1 Using a radioimmunoassay, plasma fluphenazine (FPZ) concentrations were examined in 33 schizophrenic patients during 38 intervals between injections of FPZ decanoate. Doses ranged from 12.5 to 150 mg and intervals from 1 to 5 weeks. At least three blood samples were taken between injections from each subject; also in 26 subjects additional samples were taken during the first 24 h post-injection. 2 FPZ was measurable in all plasma samples. 3 Each injection was followed by a rapid rise in plasma FPZ concentration to a maximum at 1-8 h. The height of this peak varied considerably. Within the next 12-36 h plasma FPZ fell to a level slightly above that found before injection and then remained stable until the next injection, thus confirming the steady release of FPZ from the depot over this period. 4 For the group, dose and mean plasma FPZ levels correlated strongly. 5 Despite this, there was a four-fold variation in plasma FPZ concentration among subjects receiving the same dose. 6 The FPZ level on the last day of an interval between injections was a satisfactory estimate of the mean FPZ level for the interval. 7 In one subject examined in this way, a positive correlation was found (r = 0.76) between plasma FPZ (by radioimmunoassay) and plasma prolactin levels.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 533577      PMCID: PMC1429895          DOI: 10.1111/j.1365-2125.1979.tb01045.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia.

Authors:  D A Johnson
Journal:  Br J Hosp Med       Date:  1977-06

2.  The side-effects of fluphenazine decanoate.

Authors:  D A Johnson
Journal:  Br J Psychiatry       Date:  1973-11       Impact factor: 9.319

3.  Radioimmunoassay for fluphenazine in human plasma.

Authors:  D H Wiles; M Franklin
Journal:  Br J Clin Pharmacol       Date:  1978-03       Impact factor: 4.335

4.  Plasma-fluphenazine concentrations after injection of long-acting esters.

Authors:  S H Curry; R Whelpton; P J de Schepper; S Vranckx; A A Schiff
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

5.  Prolactin, TSH, LH and FSH responses to a combined LHRH-TRH test at different stages of the menstrual cycle.

Authors:  A S McNeilly; C Hagen
Journal:  Clin Endocrinol (Oxf)       Date:  1974-10       Impact factor: 3.478

6.  Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.

Authors:  S R Hirsch; R Gaind; P D Rohde; B C Stevens; J K Wing
Journal:  Br Med J       Date:  1973-03-17

7.  Release and elimination of 14C-fluphenazine enanthate and decanoate esters administered in sesame oil to dogs.

Authors:  J Dreyfuss; J J Ross; J M Shaw; I Miller; E C Schreiber
Journal:  J Pharm Sci       Date:  1976-04       Impact factor: 3.534

8.  Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment.

Authors:  D H Wiles; T Kolakowska; A S McNeilly; B M Mandelbrote; M G Gelder
Journal:  Psychol Med       Date:  1976-08       Impact factor: 7.723

  8 in total
  16 in total

Review 1.  Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications.

Authors:  S R Marder; J W Hubbard; T Van Putten; K K Midha
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate.

Authors:  A Viala; B Ba; A Durand; F Gouezo; N Hou; A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 3.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

4.  The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.

Authors:  K K Midha; J W Hubbard; S R Marder; E M Hawes; T Van Putten; G McKay; P R May
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Effect of 1050 mg fluphenazine decanoate given intramuscularly over six days.

Authors:  H K Cheung; E C Yu
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-26

6.  Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.

Authors:  D H Wiles; R G McCreadie; A Whitehead
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Plasma levels of fluphenazine and prolactin in psychiatric patients.

Authors:  T Kitamura; D A McGovern; N W Imlah; D Wiles; A A Schiff
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988-09

8.  Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.

Authors:  A Viala; N Hou; B Ba; A Durand; H Dufour; N D'Agostino; C Berda; A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Variation in oro-facial tardive dyskinesia during depot antipsychotic drug treatment.

Authors:  T R Barnes; D H Wiles
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in Viscoleo.

Authors:  A Jørgensen
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.